Drugs Trial

Source: news.yahoo.com --- 19 days ago
HealthDay - TUESDAY, Sept. 23 (HealthDay News) -- More than half of all supporting clinical trials for U.S. Food and Drug Administration-approved Drugs remain unpublished five years after permission has been given to sell the Drugs in the United States, say University of California, San Francisco researchers. ...

Source: www.ncbi.nlm.nih.gov --- 25 days ago
Related Articles Providing patients with information about disease-modifying anti-rheumatic Drugs: Individually or in groups? A pilot randomized controlled Trial comparing adherence and satisfaction. Musculoskeletal Care. 2008 Sep 15; Authors: Homer D, Nightingale P, Jobanputra P Background: Communicating information about disease-modifying anti-rheumatic Drugs (DMARDs) before patients start treatment is a key role for some rheumatology clinical nurse specialists. This is done in our unit to promote understanding of the risks and benefits of drug therapy and encourage timely and reliable use of DMARDs. Information is routinely provided individually but this can lead to delays in starting treatment because of limited nursing resources. In this randomized Trial we tested the feasibility of giving patients, who were about to start on a DMARD, information about the drug in groups and compared this with information given individually. Methods: Adults with a clinical diagnosis of rheumatoid arthritis or psoriatic arthritis who were referred to the nursing team for counselling about starting on methotrexate, sulfasalazine or leflunomide were included. Patients who had previously taken a DMARD were not excluded and those consenting were randomized to receive drug information individually or in groups (of three to six patients). We provided all patients with written materials about the relevant drug and discussed the risks and benefits of drug ...

Source: www.investors.com --- 8 days ago
A decade ago, Fred Eshelman made a bet. The founder and chief executive of PPD added drug discovery to the company's core business. ...

Source: www.medicinenet.com --- 16 days ago
Title: Many Trial Reports on FDA-Approved Drugs Go Unpublished Category: Health News Created: 9/24/2008 2:00:00 AM Last Editorial Review: 9/24/2008 ...

Source: www.mg.co.za --- 34 days ago
The Church of Scientology is to be tried for fraud, and seven of its members for illegally prescribing Drugs, legal sources said Monday. ...

Source: www.southbendtribune.com --- 25 days ago
SOUTH BEND -- The Trial of a 42-year-old South Bend man accused of attempted murder got under way Tuesday, but not without a few bumps in the road. ...

Source: www.lloydslist.com --- 39 days ago
LAWYERS defending two Ukrainian seafarers detained in Maracaibo for more than a year have invited human rights groups to their Trial in October to highlight the abuses of the Venezuelan justice system, writes Rainbow Nelson in Caracas. ...

Source: www.norwichbulletin.com --- 26 days ago
State prosecutors are prepared to start jury selection today in a Trial for the former South Killingly fire chief accused of dealing Drugs. Former Chief William Auclair, 43, denies claims that he and former fire department chaplain Arthur Nason, 53, sold cocaine from their 231 Slater Road home. Auclair’s case is one on a list of criminal cases to be considered for a Trial by a judge when a jury pool meets today in Danielson Superior Court. Jurors are selected after a case is marked for Trial. “It may go forward, it may not,” state prosecutor Mark Stabile said of Auclair’s case. Stabile said a judge typically considers first the cases that are older and those where defendants are incarcerated. The jury selection process is also a last-chance opportunity for some cases to be resolved through plea agreements. Auclair has maintained his innocence since his Jan. 10, 2007, arrest by state police on charges of sale of narcotics, possession of narcotics, possession of marijuana and possession of drug paraphernalia. Prosecution against Nason is suspended until 2010 while he is enrolled in a diversionary substance abuse treatment program with the Connecticut Alcohol and Drug Abuse Council. Both men were charged at the outcome of an undercover investigation by members of the state police Quality of Life Task Force at Troop D in Danielson. Dating back to 2005, state police said they had gathered information from several sources that Nason, wi ...

Source: www.fwicki.com --- 21 days ago
A clinical Trial comparing psoriasis Drugs Ustekinumab made by Johnson & Johnson and Enbrel sold by Wyeth and Amgen shows that Ustekinumab is much better than Enbrel, which currently covers 75% of psoriasis ... ...

Source: www.co-neurology.com --- 32 days ago
Page: 519 DOI: 10.1097/WCO.0b013e32830f1e3b Authors: van Doorn, Pieter A; Merkies, Ingemar SJ ...

Source: www.biomedical-roadmap.co.uk --- 7 days ago
Being diagnosed with testicular cancer is blow for any man, however the chances of surviving the disease are getting better all of the time. Nevertheless, when Gary Foster aged 27 was told that he had the disease with a sixty per cent chance of survival; he wanted to get all the help that he could. The [...] ...

Source: www.ncbi.nlm.nih.gov --- 4 days ago
Related Articles A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2008 Oct 5; Authors: Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, BACKGROUND: Previous studies showing that tiotropium improves multiple end points in patients with chronic obstructive pulmonary disease (COPD) led us to examine the long-term effects of tiotropium therapy. METHODS: In this randomized, double-blind Trial, we compared 4 years of therapy with either tiotropium or placebo in patients with COPD who were permitted to use all respiratory medications except inhaled anticholinergic Drugs. The patients were at least 40 years of age, with a forced expiratory volume in 1 second (FEV(1)) of 70% or less after bronchodilation and a ratio of FEV(1) to forced vital capacity (FVC) of 70% or less. Coprimary end points were the rate of decline in the mean FEV(1) before and after bronchodilation beginning on day 30. Secondary end points included measures of FVC, changes in response on St. George's Respiratory Questionnaire (SGRQ), exacerbations of COPD, and mortality. RESULTS: Of a total of 5993 patients (mean age, 65+/-8 years) with a mean FEV(1) of 1.32+/-0.44 liters after bronchodilation (48% of predicted value), we randomly assigned 2987 to the tiotropium group and 3006 to the placebo group. Mean absolute improvements in FEV(1) in the tiotropium group were maintained throughout the Trial (ranging from 87 to ...

Source: www.ncbi.nlm.nih.gov --- 2 days ago
Related Articles Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol. 2008 Nov;20(6):652-61 Authors: Norden AD, Drappatz J, Wen PY PURPOSE OF REVIEW: Antiangiogenic Drugs are increasingly used in malignant glioma therapy. This article reviews the rationale for targeting angiogenesis in malignant gliomas, summarizes relevant clinical Trial results, and discusses promising avenues of investigation in antiangiogenic therapy. RECENT FINDINGS: Combination therapy with bevacizumab, the humanized monoclonal antibody against vascular endothelial growth factor, and irinotecan has emerged as the treatment of choice for recurrent malignant gliomas, prolonging progression-free survival markedly in comparison with historical controls. Several small molecule tyrosine kinase inhibitors of the vascular endothelial growth factor receptor are under investigation and show promise as well. SUMMARY: Antiangiogenic treatments are effective and well tolerated options for recurrent malignant glioma. Future studies will determine whether these Drugs have a role in first line therapy. Studies are in progress to elucidate mechanisms of resistance and suggest approaches to further improve survival in patients with these challenging tumors. PMID: 18841047 [PubMed - in process] ...

Source: www.ncbi.nlm.nih.gov --- 13 hours ago
Related Articles Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer. Invest New Drugs. 2008 Oct 9; Authors: Blanke CD, Beer TM, Todd K, Mori M, Stone M, Lopez C Purpose: To determine the safety and efficacy of weekly high-dose oral calcitriol and docetaxel, given to patients with non-resectable, incurable pancreatic cancer. Patients and Methods: Twenty-five patients were enrolled onto this phase II study. Patients were treated with oral calcitriol 0.5 mug/kg on day 1, followed by docetaxel 36 mg/m(2) IV on day 2, administered weekly for three consecutive weeks, followed by 1 week without treatment. Patients followed a low-calcium diet and increased their hydration. The primary end-point of the Trial was time-to-progression. Results: Three of 25 patients attained a partial response (12%, 95% CI 3 to 31) and seven (28%) achieved stable disease. Median time-to-progression was 15 weeks, and median overall survival was 24 weeks. Toxicities observed (hyperglycemia, fatigue) were mostly attributable to the docetaxel or its pre-treatment. Conclusions: This regimen of high-dose calcitriol with docetaxel may have activity in incurable pancreatic cancer, with a modest increase in TTP when compared to historical findings using single-agent docetaxel. However, results do not appear superior to those seen with gemcitabine, with or without erlotinib. PMID: 18843448 ...

Source: www.ncbi.nlm.nih.gov --- 5 days ago
Related Articles First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view. BMC Proc. 2008;2 Suppl 2:S3 Authors: Thatcher N ABSTRACT : Treatment of non-small-cell lung cancer is dependent on disease stage. For patients with metastasis or locally advanced disease, the importance of finding therapeutic schemes that may benefit this population is important. This review discusses therapeutic options for first- and second-line treatment in patients with advanced non-small-cell lung cancer. According to current data, the combination of two cytotoxic agents is the optimum first-line treatment for patients with non-small-cell lung cancer and performance status of 0-1. Addition of bevacizumab has shown to provide an even longer survival and to increase response rate. Within the first-line setting, erlotinib appears to be effective in the treatment of elderly patients who would not derive a benefit from standard chemotherapy or those refusing standard chemotherapy. The administration of erlotinib as first-line maintenance therapy is being assessed. There are currently three Drugs approved for second-line treatment of patients with advanced non-small-cell lung cancer after failure of first-line chemotherapy. These Drugs have proven to be effective in phase III trials. In the phase III Trial BR.21 study, the response rate was 8.9% in the erlonitib group, and less than 1% in placebo; median response duration ...

Source: triangle.bizjournals.com --- 5 days ago
Shares of Salix Pharmaceuticals jumped in trading Monday after the company said one of its Drugs showed good results in a late-stage human Trial. ...

Source: www.baltimoresun.com --- 2 days ago
Disputing accusations that he choked and raped a woman in a field last year, a Howard County man told a jury yesterday the alleged victim agreed to have sex in exchange for help getting Drugs. Attorneys on both sides rested their case yesterday in the Trial of Dedrick Tyrone Wilkerson of Columbia and plan to present closing arguments today. Wilkerson, an 18-year-old who was 17 at the time of the alleged incident last October, is charged with first-degree rape and assault. ...